PubMed
Thymosin alpha 1: A comprehensive review of the literature
Romani et al., 2020
Immune SupportCompoundable (US) — Approved InternationallyA
Thymosin Alpha-1
Tα1 / Zadaxin
Thymosin alpha-1 (Tα1, brand: Zadaxin) is a 28-amino acid peptide naturally produced by the thymus gland that plays a central role in modulating T-cell maturation and immune response. Approved in 40+ countries for hepatitis B, hepatitis C treatment adjuvancy, and as immune support in cancer patients. In the US, available through compounding pharmacies for immune support. Studied for COVID-19 severity reduction.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 8
- Research grade
- A
- Experience
- 100
- Activity
- 58
Overall check-ins
Trackers & reports
Overview
About Thymosin Alpha-1
Thymosin alpha-1 (Tα1, brand: Zadaxin) is a 28-amino acid peptide naturally produced by the thymus gland that plays a central role in modulating T-cell maturation and immune response. Approved in 40+ countries for hepatitis B, hepatitis C treatment adjuvancy, and as immune support in cancer patients. In the US, available through compounding pharmacies for immune support. Studied for COVID-19 severity reduction.
- Category
- Immune Support
- Regulatory status
- Compoundable (US) — Approved Internationally
- Also known as
- Tα1 / Zadaxin
- Self-reports
- 7
Community
What 7 users report
7 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
7
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Inflammation
1
Self-reported dose per injection
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.4–2 mg
0.4–0.6 mg
4
1–2 mg
3
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Research
Cited research (6)
Source
PubMed
Thymosin alpha 1: past clinical experience and future promise
Tuthill et al., 2010
PubMed
Thymosin alpha 1 as adjuvant therapy for melanoma and other cancers
Garaci et al., 2014
ClinicalTrials.gov
Thymosin alpha-1 studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach
Naylor et al., 2018
PubMed
Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection
Al-Mahtab et al., 2016
Tools
Explore more
Explore
More ways to learn about Thymosin Alpha-1 from observational PeptIQ data.
Compare with
Help
Frequently asked
What do PeptIQ users report about Thymosin Alpha-1?
This page summarizes 7 anonymized self-reports from PeptIQ users who track Thymosin Alpha-1, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Thymosin Alpha-1?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Thymosin Alpha-1?
6 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Thymosin Alpha-1 safe to use?
This wiki does not assess safety or recommend use. Thymosin Alpha-1 is listed as Compoundable (US) — Approved Internationally. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Thymosin Alpha-1?
This wiki summarizes observational community reports and linked citations for Thymosin Alpha-1. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for Thymosin Alpha-1 for study-level context — not medical advice.
What is the legal status of Thymosin Alpha-1?
Thymosin Alpha-1 is listed in PeptIQ as Compoundable (US) — Approved Internationally. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of Thymosin Alpha-1?
Safety data quality for Thymosin Alpha-1 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on Thymosin Alpha-1?
This page links 6 indexed sources for Thymosin Alpha-1. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.